Moderna Inc
MRNA: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|^M | LOCK|$v& | LOCK|qsL&^!H |
Moderna: Failure of Cytomegalovirus Vaccine Further Increases Pressure on Oncology Pipeline
On Oct. 22, Moderna announced that its cytomegalovirus vaccine candidate mRNA-1647 failed to show significant efficacy in a phase 3 trial for congenital CMV. Shares fell 4% after hours.
